Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04092179 |
|
Recruitment Status :
Terminated
(Insufficient Funding)
First Posted : September 17, 2019
Last Update Posted : January 24, 2024
|
Sponsor:
University Health Network, Toronto
Collaborators:
Celgene
AbbVie
Information provided by (Responsible Party):
University Health Network, Toronto
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | October 26, 2023 |
| Actual Study Completion Date : | October 26, 2023 |